At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Androxal (enclomiphene citrate) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men
In Brief
A Phase 2 clinical trial evaluating Androxal (enclomiphene citrate) and Testosterone for Secondary Hypogonadism. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
The study will determine the effects of three doses of Androxal(enclomiphene citrate)on morning testosterone versus AndroGel(approved topical treatment)in men with low testosterone (\<350 ng/dL)after 6 weeks of continuous dosing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSecondary Hypogonadism
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJul 2011
Primary CompletionOct 2011
TodayJul 2026
First PostedJul 1, 2011
Enrollment StartJun 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.0 years ago
Interventions
Androxal (enclomiphene citrate)drug
capsule oral 1X a day 6 weeks
Testosteronedrug
topical gel 1X a day 6 weeks